You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
Dermatology
How type 2 cytokines can amplify inflammatory response in CSU
Dr. Thomos Casale explores the role of Th2 inflammation in CSU, highlighting the impact of IgE autoantibodies and the need for targeted therapies against Th2 cytokines.
MD
Thomas Casale
Learning objectives
Explain the role of IgE autoantibodies and their interaction with mast cells in the pathophysiology of CSU.
Understand the significance of targeting Th2 cytokines for developing targeted therapies in CSU.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
All rights reserved. MAT-US-2305040 v3.0-P Exp. Date: 11/24/2025
All Rights Reserved.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.